| Similar Articles |
|---|
 |
The Motley Fool
August 3, 2007
Brian Orelli |
Another Headache for Pozen Investors Drugmaker Pozen might have to run one more trial for the FDA for its migraine drug.   |
The Motley Fool
January 16, 2008
Brian Orelli |
Headache Almost Over for Pozen The drug is safe; hopefully that's all the FDA wanted to know. |
The Motley Fool
October 8, 2007
Brian Orelli |
Pozen Submits Safety Data Will Pozen's response to its second approvable letter be enough? Investors may want to take this with a grain of salt. |
The Motley Fool
February 24, 2011
Brian Orelli |
Youth in Revolt Against POZEN POZEN fails to get a pediatric extension on its migraine drug. |
The Motley Fool
May 3, 2010
Brian Orelli |
While You Were Reveling in Dendreon's Win The FDA has approved Vimovo, an arthritis drug from Pozen and AstraZeneca, and Bristol-Myers Squibb also got a decision from the FDA, but it wasn't the positive kind. |
The Motley Fool
April 17, 2008
Brian Orelli |
Headache Over for Pozen and Glaxo? The duo's FDA headache regarding their migraine drug is over, but a new one is about to begin. |
The Motley Fool
May 17, 2007
Mike Havrilla |
Pozen Poised for Profits The pharmaceutical reported first-quarter results. But investors should look to buy shares of this company because of how its results may look later this year. |
The Motley Fool
August 3, 2006
S.J. Caplan |
AstraZeneca's Path to Avoid Pain The pharmaceutical giant partners with Pozen to co-develop a drug. Take heart, AstraZeneca shareholders! No queasy stomachs are expected in your future. |
The Motley Fool
July 17, 2007
Andrew R. Vaino |
Problems Posed for Pozen If its latest drug isn't approved, the pharmaceutical's stock will clearly tank. Any benefits stemming from the drug's successful approval are harder to gauge. |
The Motley Fool
August 17, 2007
Brian Orelli |
Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully. |
BusinessWeek
February 27, 2006
Gene G. Marcial |
Pozen's Trexima: Going To Market With Glaxo Pozen's Trexima is a new drug for severe headaches that analysts claim is more effective and faster-acting than GlaxoSmithKline's $1 billion-a-year blockbuster Imitrex. |
The Motley Fool
December 4, 2008
Brian Orelli |
Poor Pozen It's not often that you see a drug developer release data from two positive phase 3 trials for its lead pipeline compound and see its shares fall more than 4%, but that's what happened to Pozen. |
Science News
January 6, 2001 |
Migraine: What a Pain! The Journal of the American Medical Association has developed a Web site that serves as a repository of background information and news of use to migraine victims and their families. Keep up with the latest science by checking abstracts of new journal articles... |
BusinessWeek
June 13, 2005
Arlene Weintraub |
Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances. |
The Motley Fool
April 16, 2011 |
Pozen Wins Injunction Blocking Generic Migraine Drug The ruling against Par Pharmaceutical comes just in time for Pozen. |
The Motley Fool
September 17, 2011
Chris Seper |
Pozen's Digital Marketing Plan: A Prescription for the Pharma Industry? The company looks to get in tune with social media. |
The Motley Fool
October 9, 2006
Brian Lawler |
The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field. |
The Motley Fool
November 26, 2011
Stephanie Baum |
Pozen Inks $75 Million Royalty Deal for Treximet The pharma sells U.S. rights for the migraine drug to Canada's national pension fund. |
The Motley Fool
January 25, 2005
Charly Travers |
Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs. |
The Motley Fool
January 28, 2011
Luke Timmerman |
Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up. |
The Motley Fool
August 28, 2006
Brian Lawler |
The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks. |
National Real Estate Investor
May 1, 2006
F. R. Skinner |
Bulking Up On Biotech Investing in the development of a highly unique, medical-grade building is only going to appeal to a select niche of investors. But with biotech returns averaging some 1% to 2% higher than the general office market, it is a smart play for investors wanting a diversified portfolio. |
The Motley Fool
November 18, 2009
Jennifer Schonberger |
Cleaning Up the Crisis MFS Investment Management chairman and author Bob Pozen discusses the current state of the economy. |
The Motley Fool
October 16, 2007
Brian Orelli |
Pozen Hedges Its Bets As promised, Pozen and partner GlaxoSmithKline announce that the pair have submitted a response to their approvable letter for Trexima, and that they plan to do an additional just-in-case safety trial. |
The Motley Fool
May 1, 2007
Mike Havrilla |
Heads Up, Biotech Investors Big news is in the offing for these companies. Pozen... Progenics... Zymogenetics... etc. |
The Motley Fool
August 18, 2008
Zoe Van Schyndel |
Funds for a Sick Economy? The biotech sector has been a sleeper with positive returns. Take a look at two biotech mutual funds that are performance leaders. |
The Motley Fool
July 14, 2005
Stephen D. Simpson |
Dueling Fools: Protein Design Labs Bear Protein Design Labs could be a big winner, or a major loser. The biotech has a strong business, but today's stock price isn't "great." |
Managed Care
May 2004
Dodick & Lipsy |
Advances in Migraine Management: Implications for Managed Care Organizations In response to the expense of new migraine therapies, treatment practices aimed at controlling direct costs are now the norm. |
The Motley Fool
December 14, 2004
Charly Travers |
Genetics of a Rule Breaker Investing is a lifelong learning process. We never know everything, but it is important we strive to learn from the lumps we take along the way. Here are some hard-earned tips from a biotech investor. |
American Family Physician
February 15, 2002 |
Migraine Headache in Children and Adolescents Do children get headaches?... What is a migraine headache?... Do many children get migraine headaches?... What causes migraine?... How is migraine diagnosed?... What can help a headache?... How can my child keep from having migraine headaches?... etc. |
The Motley Fool
December 8, 2009
Jennifer Schonberger |
The Economy and the Markets: Where Are We Now? MFS Investment Management chairman Bob Pozen discusses the state of the economy. |
American Family Physician
December 15, 2006
Mark H. Ebell |
Point-of-Care Guides Clinical Question: What is the best way to diagnose migraine in patients presenting with headache?... Evidence Summary: Headache is a common reason for primary care office visits and is a complaint in more than 1% of patient visits... |
The Motley Fool
April 4, 2005
John Reeves |
Returns That Defy the Imagination Want to save lives while pursuing a high-growth investment strategy? Try exploring the biotech frontier. |
The Motley Fool
December 11, 2009
Jennifer Schonberger |
How Can We Revive the Securitization Market? Believe it or not, securitized loans made up a larger percentage of lending. Bob Pozen, chairman of MFS Investment Management has a way to revitalize the securitization market. |
The Motley Fool
December 16, 2011
Brian Orelli |
Biotech Royalties, Almost as Good as Cash They're flexible, and all royalties have value. |
BusinessWeek
November 10, 2003
Arlene Weintraub |
Biotech Startups: Take Your Time Until products are close to approval, the public shouldn't share the risk |
The Motley Fool
December 10, 2009
Jennifer Schonberger |
Financial Crises Aren't So Rare. Invest Accordingly. The chairman of MFS Investment Management shares his thoughts on crises -- and our reactions to them. |
